KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Assets: 2009-2025

Historic Assets for Arbutus Biopharma (ABUS) over the last 15 years, with Sep 2025 value amounting to $97.7 million.

  • Arbutus Biopharma's Assets fell 30.43% to $97.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.7 million, marking a year-over-year decrease of 30.43%. This contributed to the annual value of $131.7 million for FY2024, which is 8.79% down from last year.
  • Per Arbutus Biopharma's latest filing, its Assets stood at $97.7 million for Q3 2025, which was down 5.38% from $103.3 million recorded in Q2 2025.
  • Arbutus Biopharma's Assets' 5-year high stood at $236.9 million during Q1 2022, with a 5-year trough of $97.7 million in Q3 2025.
  • For the 3-year period, Arbutus Biopharma's Assets averaged around $142.9 million, with its median value being $144.4 million (2023).
  • In the last 5 years, Arbutus Biopharma's Assets surged by 61.98% in 2022 and then crashed by 35.48% in 2025.
  • Arbutus Biopharma's Assets (Quarterly) stood at $204.5 million in 2021, then declined by 4.43% to $195.4 million in 2022, then declined by 26.11% to $144.4 million in 2023, then fell by 8.79% to $131.7 million in 2024, then slumped by 30.43% to $97.7 million in 2025.
  • Its last three reported values are $97.7 million in Q3 2025, $103.3 million for Q2 2025, and $117.0 million during Q1 2025.